These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16758571)

  • 1. Clinical trials in chronic neuromuscular diseases: Proceedings of a colloquium at Totts Gap Institute, Bangor, PA, sponsored by the Muscular Dystrophy Association.
    Wolf S; Lewis NJ
    Muscle Nerve; 1985; 8(6):451, 454-92. PubMed ID: 16758571
    [No Abstract]   [Full Text] [Related]  

  • 2. The CNDR: collaborating to translate new therapies for Canadians.
    Korngut L; Campbell C; Johnston M; Benstead T; Genge A; Mackenzie A; McCormick A; Biggar D; Bourque P; Briemberg H; O'Connell C; Dojeiji S; Dooley J; Grant I; Hogan G; Johnston W; Kalra S; Katzberg HD; Mah JK; McAdam L; McMillan HJ; Melanson M; Selby K; Shoesmith C; Smith G; Venance SL; Wee J;
    Can J Neurol Sci; 2013 Sep; 40(5):698-704. PubMed ID: 23968944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neuromuscular disease: health care accessibility in the Nord-Pas-de- Calais region].
    Donzé C; Delattre S; Viet G; Thevenon A
    Rev Neurol (Paris); 1999 Dec; 155(12):1063-70. PubMed ID: 10637926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperation is key, say neuromuscular-disease researchers.
    Butcher J
    Lancet Neurol; 2007 Apr; 6(4):298-9. PubMed ID: 17438644
    [No Abstract]   [Full Text] [Related]  

  • 5. Neuromuscular diseases: milestones in development of treatments.
    Bushby K
    Lancet Neurol; 2011 Jan; 10(1):11-3. PubMed ID: 21163438
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term nasal ventilation in neuromuscular disorders: report of a consensus conference.
    Robert D; Willig TN; Leger P; Paulus J
    Eur Respir J; 1993 Apr; 6(4):599-606. PubMed ID: 8491312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network.
    Shimizu R; Ogata K; Tamaura A; Kimura E; Ohata M; Takeshita E; Nakamura H; Takeda S; Komaki H
    BMC Health Serv Res; 2016 Jul; 16():241. PubMed ID: 27401940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of illness for neuromuscular diseases in the United States.
    Larkindale J; Yang W; Hogan PF; Simon CJ; Zhang Y; Jain A; Habeeb-Louks EM; Kennedy A; Cwik VA
    Muscle Nerve; 2014 Mar; 49(3):431-8. PubMed ID: 23836444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives on the treatment of neuromuscular disease.
    Griggs RC
    Adv Neurol; 1977; 17():1-12. PubMed ID: 196498
    [No Abstract]   [Full Text] [Related]  

  • 10. [Collection of presentations at the meeting of the European Alliance of Muscular Dystrophy Associations, Belgrade, 1976].
    Neurologija; 1977; 25 Spec No():1-120. PubMed ID: 42858
    [No Abstract]   [Full Text] [Related]  

  • 11. An update on RNA-targeting therapies for neuromuscular disorders.
    Jirka S; Aartsma-Rus A
    Curr Opin Neurol; 2015 Oct; 28(5):515-21. PubMed ID: 26280937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Outcomes measures used in clinical trials in neuromuscular diseases].
    Boussaïd G; Vuillerot C; Pisco Domingos J; Dany A; Ricci E; Servais L; Constant Boyer F
    Med Sci (Paris); 2018 Nov; 34 Hors série n°2():49-50. PubMed ID: 30418151
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of technology in the lives of neuromuscular patients.
    Simmons Z
    Muscle Nerve; 2020 Jun; 61(6):681. PubMed ID: 32413246
    [No Abstract]   [Full Text] [Related]  

  • 14. Profiles of neuromuscular diseases. Design of the protocol.
    Fowler WM; Abresch RT; Aitkens S; Carter GT; Johnson ER; Kilmer DD; McCrory MA; Wright NC
    Am J Phys Med Rehabil; 1995; 74(5 Suppl):S62-9. PubMed ID: 7576423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives on best practices for gene therapy programs.
    Cheever TR; Berkley D; Braun S; Brown RH; Byrne BJ; Chamberlain JS; Cwik V; Duan D; Federoff HJ; High KA; Kaspar BK; Klinger KW; Larkindale J; Lincecum J; Mavilio F; McDonald CL; McLaughlin J; Weiss McLeod B; Mendell JR; Nuckolls G; Stedman HH; Tagle DA; Vandenberghe LH; Wang H; Wernett PJ; Wilson JM; Porter JD; Gubitz AK
    Hum Gene Ther; 2015 Mar; 26(3):127-33. PubMed ID: 25654329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
    Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
    Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and management of adult hereditary cardio-neuromuscular disorders: A model for the multidisciplinary care of complex genetic disorders.
    Sommerville RB; Vincenti MG; Winborn K; Casey A; Stitziel NO; Connolly AM; Mann DL
    Trends Cardiovasc Med; 2017 Jan; 27(1):51-58. PubMed ID: 27452966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland.
    Lefter S; Hardiman O; Ryan AM
    Neurology; 2017 Jan; 88(3):304-313. PubMed ID: 27927941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic advances in neuromuscular diseases].
    Serrano-Munuera C; Illa I
    Neurologia; 1999 Dec; 14 Suppl 6():36-45. PubMed ID: 10659604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fiction: lemon, with a twist.
    Brooke MH
    Neurology; 2003 Dec; 61(12):1824-5. PubMed ID: 14694065
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.